Skip to main content

Table 3 Diagnostic performance of a biomarker panel for DLB versus other clinical groups

From: Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach

DLB versus

Accuracy (95% CI)

Sensitivity (95% CI)

Specificity (95% CI)

All non-DLB

0.82 (0.75–0.89)

0.69 (0.41–0.98)

0.83 (0.74–0.90)

Controls

0.84 (0.77–0.89)

0.77 (0.46–1.00)

0.85 (0.76–0.93)

PD

0.79 (0.69–0.87)

0.72 (0.43–0.93)

0.80 (0.66–0.90)

AD

0.89 (0.85–0.99)

0.85 (0.79–0.99)

1.00 (1.00–1.00)

FTD

0.76 (0.61–0.92)

0.73 (0.55–0.95)

0.86 (0.59–1.00)

  1. All protein levels were Z transformed according to the mean and standard deviation in controls
  2. Abbreviations: AD Alzheimer’s disease, DLB Dementia with Lewy bodies, FTD Frontotemporal dementia, PD Parkinson’s disease
Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326